Haematology


Our Team

Professor  Hang Quach | Director of Clinical Haematology | Director of Haematology Clinical Research
Haematologist 
Ph: (03) 9231 2030

A/Prof Merrole Cole-Sinclair | Director of Laboratory Haematology
Haematologist Ph: (03) 9231 3996

Dr Matthew Ku | Deputy Director of Haematology Clinical Research
Haematologist (Trials) Ph: (03) 9231 2030

A/Prof Ali Bazargan
Haematologist (Trials)

Dr Kritika Chaiwatanatorn
Haematologist    

Dr Anne Dykes
Haematologist

Dr Robin Filshie 
Haematologist

Dr Masa Lasica
Haematologist (Trials)

Dr Newton Lee        
Haematologist

Dr Slavisa Ninkovic
Haematologist

Dr Shirlene Sim
Haematologist

Dr Shuh Tan
Haematologist (Trials)

All our Haematologists can be contacted via St Vincent's Switchboard on Ph: (03) 9231 2211

Haematology Clinical Research Unit

Haematology Clinical Research Unit - Current Open to recruitment trials as at Jul 2021 (listed below)

For more information please contact:
Lisa Demosthenous
Manager of Haematology Clinical Research Unit
lisa.demosthenous@svha.org.au
Ph: (03) 9231 3182

Prof Hang Quach, MBBS (Hons) SpecCertOC FRACP FRCPA MD
Director | Haematology Clinical Research Unit | St Vincent’s Hospital
Interim Director | Clinical Haematology Service | St Vincent’s Hospital
hang.quach@svha.org.au

Dr Matthew Ku, MBBS SpecCertOC FRACP FRCPA PhD
Deputy Director of Haematology Clinical Research Unit | St Vincent’s Hospital
Haematologist & Lymphoma Lead | St Vincent’s Hospital
matthew.ku@svha.org.au

Multiple Myeloma

Smouldering

Ithaca (SMM)

Phase 3 randomized, open label, multicenter study of Isatuximab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Open to recruitment

Newly Diagnosed

GSK2857916 DREAMM 9 (ND MM)

A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

Open to recruitment

IRiL (ND MM)

A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma

Open to recruitment

ALLG MM22 / FRAIL-M (ND MM)

Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study

Pending to Open

ALLG MM23 SeaLAND (ND MM)

An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma

Open to recruitment

Relapsed Refractory

AbbVie M15-654 (R/R MM)

A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma

Open to recruitment

AMaRC 19-02 BelaCarD (R/R MM)

A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma.

Open to recruitment

AMG701 ParadigMM-1B (R/R MM)

A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Pending to open

BGB-11417-105 (R/R MM)

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in

Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Pending to open

CC-220-MM-002 EXCALIBER (R/R MM)

A Phase 3, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab And Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, And Dexamethasone (Dvd) In Subjects With Relapsed Or Refractory Multiple Myeloma

Pending to open

Celgene CC-92480-MM-001 (R/R MM)

A Phase 1 Multicenter, Open-Label Study To Assess The Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Open to recruitment

GSK2857916 DREAMM 3 (R/R MM)

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

GSK2857916 DREAMM 5 (R/R MM)

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) in Combination with Anti- Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

GSK207497 DREAMM 6 (R/R MM)

A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Treatment A), or Bortezomib Plus Dexamethasone (Treatment B) in Participants with Relapsed / Refractory Multiple Myeloma

Open to recruitment

GSK2857916 DREAMM 8 (R/R MM)

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma

Open to recruitment

Janssen 64007957MMY1004 MajesTEC-2

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma

Open to recruitment

Pfizer MAGNETISMM-3

An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Elranatamab (Pf-06863135) Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody

Open to recruitment

Acute Myeloid Leukaemia & Myelodysplastic Syndrome

Treatment

Naïve

Newly diagnosed

ALLG AML M23 (HOVON) (TN AML, TN MDS)

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Open to Recruitment

ALLG AML M25 (INTERVENE) (ND AML)

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia

Open to Recruitment

M15-954 (Verona) (ND MDS)

A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)

Open to recruitment

KER050-MD-201 (ND MDS)

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Open to recruitment

Relapsed Refractory

BGB-11417-103 (R/R Myeloid Malignancies)

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Open to recruitment

Chronic Lymphocytic Leukaemia

Treatment Naïve

BGB3111_304 (TN CLL)

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma

Open to recruitment

Treatment Naïve & Relapsed Refractory

BGB-11417-101 (TN, R/R CLL)

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

Open to recruitment

Relapsed Refractory

Assure (R/R CLL)

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic leukaemia

Open to Recruitment

PCYC-1145-LT (R/R CLL)

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Need to be from an eligible Parent study

Chronic Myeloid Leukaemia

Treatment Naive

ASCEND-CML study CML13 (ND CML)

An ALLG single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia

Open to recruitment

Lymphomas

Treatment Naïve

ALLG NHL30 PETReA (TN FL)

Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

Open to Recruitment

BGB-3111-306 Mangrove (TN MCL)

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Open to recruitment

MOR208C310 FRONTmind (TN DLBCL)

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)

Pending to open

Treatment Naïve &

Relapsed Refractory

Ascentage APG2575WU101 MAPLE-1 (TN WM, R/R WM)

A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenström Macroglobulinemia

Open to recruitment

Relapsed Refractory

ALLG NHL33 – WAMM (R/R MCL)

An ALLG Window study of Acalabrutinib plus Rituximab followed by R-DHAOx+ASCT in fit Mantle Cell Lymphoma

Open to recruitment

Ascentage APG-2575-001 (R/R CLL, WM, DLBCL, AML, NHL, MCL)

A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2575 in Patients with hematologic malignancies

Open to recruitment

BGB-11417-101 (R/R) B-cell NHL

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

Open to recruitment

BGB-3111-LTE1 (R/R DLBCL, FL, CLL, SLL, MCL)

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B Cell Malignancies

Need to be from an eligible Parent study

BGB-A317-210 TIRHOL (R/R cHL)

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Open to recruitment

Genentech GO29781 (R/R DLBCL, FL, MZL, NHL, RT, SLL, MCL)

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Dose of BTCT4465A in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic leukaemia

Open to recruitment

GENMAB GCT3013-01 (R/R DLBCL and FL)

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

Open to recruitment

GILEAD Magrolimab (R/R NHL)

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

Open to recruitment

IGM Biosciences IGM-2323-001 (R/R NHL)

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas

Open to recruitment

MERCK (MK-4280-003) (R/R HL, DLBCL, NHL)

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Open to recruitment

Roche GO41943 (R/R DLBCL)

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of RO7082859 or Mosunetuzumab (RO7030816) in Combination with Gemcitabine plus Oxaliplatin in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Open to recruitment

TG-1701-101 (R/R CLL, WM, NHL)

A Phase 1 Pharmacokinetic and Pharmacodynamics Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients with B-Cell Malignancies

Open to recruitment

Bleeding Disorders

DIAAMOND (Aplastic Anaemia)

Section A: Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia - The DIAAMOND Ava-FIRST Trial

Section B: Avatrombopag iN Relapsed or Refractory severe aplastic anaemia as EXtra Therapy – The DIAAMOND Ava-NEXT Trial

Open to recruitment

TREATT

TREATT Trial to Evaluate Tranexamic acid therapy in Thrombocytopenia. A double blind randomized controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with hematological malignancies with severe thrombocytopenia.

Open to recruitment

Registries / Other

Myeloma 1000 Registry

The Myeloma 1000 Project

Open to recruitment

MRDR Registry

Myeloma & Related Diseases Registry

Open to recruitment

NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)

Open to recruitment

Carfilzomib Retrospective 20170766 (R/R MM)

Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific

Open to recruitment

C-SMART

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial

Pending to Open

COVID Study

A Multi-Centre National study of COVID-19 infection in Cancer patients

Open to recruitment

MOR208C213 (RE-MIND2) (R/R DLBCL)

An observational retrospective cohort study of systemic therapies for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), to compare outcomes to those from Tafasitamab + Lenalidomide in the L-MIND study

Open to recruitment


Health Pathways

HealthPathways Melbourne is an online portal designed to be used by general practice at the point of care to guide best practice assessment, management and referral of common clinical conditions.

 

Please Note:
This is a public outpatient service. All patients need to be referred to us by a GP. Please see your GP if you believe you would benefit from a referral to this clinic. Many doctors have private consulting suites as well as working in the public hospital system. This is entirely separate from St Vincent’s and our staff do not have any information about the private consulting practices of doctors.

 

Mandatory field(s) marked with *